Bullish Case: Return-surface (known) likelihood ridge sits near -10% to +20% over ~1–2y, leaving room for re-rating; today’s backwardation/high BDTX IV (inferred) suggests repricing can occur on discrete catalysts. Phase II readout already shows mPFS 15.2m, ORR 60% and CNS ORR 86% with fewer severe TRAEs after dose reduction (known). If FDA pivotal-plan discussion later in 2026 goes smoothly, upside pocket toward +30–80% remains plausible (uncertain).

Bearish Case: Recent BDTX prints have been flat-to-down (known: -16% YoY, -26% since a month ago). Helium AI forecast is slightly bearish (-1.24%) with ~zero correlation (known), so directional edge is limited. Return-surface shows non-trivial likelihood in -30% to -60% tail (inferred). SPY IV surface implies elevated, downside-skewed market uncertainty into ~90–260 days (known). With small Phase II plus safety/dilution/FDA-design ambiguity (uncertain), downside moves may dominate.

Potential Outcomes:

Calibration (from Mar31): BDTX is ~-16% YoY and flat recently; June-squeeze upside odds reduced.

1. 23%: FDA agrees workable pivotal design (falsifiable via FDA-agreed protocol/press note) → +15–35%.
2. 25%: Safety/tolerability or CNS efficacy fades in follow-up (new cohort/CSRs) → -25–55%.
3. 20%: Equity financing/dilutive issuance around funding needs → -20–40%.
4. 17%: SPY risk-off keeps downside IV bid → -10–30%.
5. 15%: Stronger efficacy update (e.g., GBM/extra NSCLC cohorts) → +40–80%.

June 05, 2026